Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4). SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee's continued service with the Company. The stock options that were granted are subject to an exercise price of $82.62 per share, which is equal to the closing price of the Company's common stock on July 15, 2026 and will vest over 4 years, with 1/4th of the shares underlying the employee's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee's continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted. The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics' MYQORZO(R)(aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to discuss the results with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube. Disclaimer Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption "Risk Factors" in Cytokinetics' latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS(R) and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. MYQORZO(R) is a registered trademark of Cytokinetics in the U.S. and the European Union.

What this Cytokinetics insider sale might mean with the stock up 110%. Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake. Key points. * The insider liquidated 7,500 shares at a weighted average price of $82.02. * The disposition represented 2% of the executive's total reported equity holdings. * Following the transaction, the CEO maintains direct ownership of 377,820 shares and indirect ownership of 4,166 shares held through two family trusts. * 10 stocks we like better than Cytokinetics" Robert I. Blum, president & CEO of Cytokinetics, Incorporated (CYTK +0.75%), reported a sale of 7,500 shares of common stock on July 13, 2026, according to an SEC Form 4 filing. Transaction summary. | Metric | Value | | Transaction value | $615,150 | | Shares sold | 7,500 | | Post-transaction shares (directly held) | 377,820 | | Post-transaction shares (indirectly held) | 4,166 | | Post-transaction value | $31.41 million | Transaction value based on SEC Form 4 weighted average sale price ($82.02); post-transaction value based on July 13, 2026 market close ($82.24). Key questions. * What were the mechanics of this transaction? The transaction involved the exercise of 7,500 stock options at a strike price of $10.60 per share, with the resulting equity immediately sold at a weighted average price of $82.02. * Who manages the indirect equity holdings reported in this filing? The 4,166 shares held indirectly are divided between the Bridget Blum 2003 Irrevocable Trust and the Brittany Blum 2003 Irrevocable Trust, which both hold 2,083 shares. * What is the scale of the insider's remaining exposure? In addition to the 381,986 shares of common stock held across direct and indirect accounts, the CEO continues to hold 186,745 derivative securities. Company overview. | Metric | Value | | Share Price (as of market close 2026-07-13) | $82.24 | | Market Capitalization | $10.2 billion | | Revenue (TTM) | $105.8 million | | Net Income (TTM) | -$829.6 million | Company snapshot. * Cytokinetics is a biopharmaceutical company that discovers, develops, and commercializes novel muscle activators and muscle inhibitors for the treatment of debilitating diseases, with MYQORZO, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, serving as its primary marketed product. * The company generates revenue through the commercialization of its proprietary therapeutic compounds, including MYQORZO and pipeline candidates such as Aficamten and omecamtiv mecarbil, which target cardiac and skeletal muscle disorders. * Cytokinetics' primary customers are healthcare providers and patients with rare genetic and acquired cardiac conditions, with a strategic focus on the treatment of hypertrophic cardiomyopathy and related muscle-mediated diseases in the United States and international markets. Cytokinetics operates as a clinical-stage to commercial-stage biopharmaceutical enterprise with a market capitalization of roughly $10 billion, leveraging its proprietary muscle biology platform to develop targeted therapeutics for unmet medical needs in cardiac and skeletal muscle disorders. The company has achieved significant clinical validation with MYQORZO's market approval and maintains a robust pipeline of investigational compounds, positioning it as a specialized player in the rare disease and cardiology therapeutic space. What this transaction means for investors. This sale ultimately looks like a CEO cashing in some deep-in-the-money options right as his company's first drug launch takes off, which isn't a signal to worry about. Blum still holds nearly 382,000 shares across direct and indirect accounts, plus 186,745 options, so the overwhelming majority of his exposure is untouched. With the stock up 110% over the past year, a CEO converting cheap options on a fraction of his stake is just diversification, plain and simple. The reason he's holding the rest is probably the launch itself and a lot of traction since. Cytokinetics booked its first U.S. product revenue in the first quarter, $4.8 million from MYQORZO in roughly nine weeks, with more than 275 doctors prescribing it to about 680 patients. The pivotal ACACIA-HCM trial also hit both primary goals, opening a path to expand the drug's use, and about $1.1 billion in cash funds the rollout. Blum called the launch a significant opportunity ahead. The firm has since launched the drug in Germany, as of last month, and gross proceeds of $805 million from an offering of common stock. Second-quarter earnings should provide clarity into how things have fared. Should you buy stock in Cytokinetics right now? Before you buy stock in Cytokinetics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and the Cytokinetics wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $370,332!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,272,280!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss Stock Advisor's latest top 10 stocks, and join an investing community built for the long haul. *Stock Advisor returns as of July 22, 2026.

Edgewise data power rival to BMS and Cytokinetics toward phase 3. * June 16, 2026 Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics.